KASTEN INC COM USD0.001 (OTCMKTS:KAST) took over the shell of the previous company, and started to operate as a public company back in November 2016. Shares started to trade, as the new business, in the last week rallying from $0.50 cents to $0.70 cents then crashing to $0.20 on big volume.
It’s common for shareholders to value the trading shares closer to what they expect this revenue to do in future quarters. Stocks are always a reflection of the revenue they make, and the current industry multiple.
KASTEN INC COM USD0.001 (OTCMKTS:KAST) announced that the past few weeks have been a very exciting time for Kasten/DAKOTA Life Sciences. The merger brought the DAKOTA experience in the life sciences sector, proprietary technologies, and multiple ready-for-market pharmaceutical products. This includes DAKOTA’s prescription development pipeline that is quite advanced in several product areas.
The Kasten team brings considerable relationships and experience in product sales and marketing, as well as a capital markets capability to direct the future growth. The merger resulted in a capital restructuring that retired 107 million existing Kasten common shares. After giving effect to the merger with Dakota, Kasten has approximately 62 million shares outstanding.
Find out when $KAST stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
KAST 10-Day Chart Below:
The company expects that the first consumer launch will be in the area of Over-The-Counter (OTC) medication for fungal infections of toenails. Our patent and trademark ownership related to the proprietary compound known as the Thin-Nail® antifungal cream enables a dramatic improvement to toenail treatments. ThinNail OTC is designed to rapidly kill fungal infections in the toenail through its proprietary penetration of the nail to effectively deliver drug where it is most needed.
The inventor of the ThinNail® medication the company uses for the toenail fungal infections, Dr. Lorri Riley, is a well-respected podiatrist with an active medical and research podiatry practice. She has worked closely with the Company since they acquired her intellectual property several years ago.
The Company continues its progress on a prescription version of the ThinNail product. This patented Rx product is designed to be radically effective compared to other prescription products. Our technology enables us to kill the more serious cases of toenail fungal infection (known by its medical term as “onychomycosis”) and to do so in about half the time, with less cost and less drug exposure to the consumer than existing products.
Another 2017 product release is expected to be in the topical antimicrobial (antibiotic) space. The continuing global challenges from resistant bacteria, requires a sophisticated medical response. Karsten addresses this critical need with a proprietary drug delivery system that they refer to as Site Specific Penetration Technology (“SSPT™”). This delivery system enables certain legacy antibiotics to perform as if they were newly developed, and to be highly effective against resistant infections.
The SSPT drug delivery system will also be used in the prescription antibiotic that is advancing through development. Following FDA approval, our prescription antibiotic with our unique SSPT delivery system will address the large population of people with diabetic foot ulcers.
This year should see an exciting launch of products, as well as a likely site selection for future operations.
Kasten, Inc. (OTCMKTS:KAST) is a biopharmaceutical company focused on the acquisition, development, and commercialization of pharmaceuticals designed to prevent and treat serious conditions that challenge the spread of bacteria, specifically hard to eliminate bacteria. This is a niche product on the front end where the company is looking to address a larger problem on the back-end. The recent activity in shares shows that investors are paying attention to what develops here.
We like the action lately, and the boomer audience who invest in this sector niche will associate with the solutions the company seeks. They also may look down through their flip flops and recognize they may want to test the product and take some action in these new shares as the company develops the story. For continuing coverage on shares of $KAST stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!